This IL-6 trans-signaling pathway plays major roles in a range of inflammatory conditions (e.g., rheumatic diseases, inflammatory bowel diseases, obesity), and is the target of anti-IL-6 therapies (e.g., tocilizumab) (1). Here, IL6 is linked to rheumatic disorder.